Finally, and although there are only two ASXL1+ patients in the AML‐NOS control group, we observe some common characteristics with AML‐MRC patients with ASXL1 mutation, highlighting the presence of leukocytosis in both and myelomonocytic morphological subtype. This evidence concerns the gene ASXL1 and Increased total leukocyte count.